Equivocal and definite interstitial lung abnormalities as risk factors for trastuzumab deruxtecan-related interstitial lung disease in breast cancer
Open Access
- 7 October 2026
- journal article
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 31 (11)
Abstract
Background: Trastuzumab deruxtecan (T-DXd) is effective for advanced breast cancer but is associated with interstitial lung disease (ILD). The clinical relevance of baseline interstitial lung abnormalities (ILAs), including subtle equivocal findings, remains unclear. Methods: This retrospective cohort study included consecutive patients with advanced or recurrent breast cancer who initiated T-DXd at a tertiary hospital in Japan between June 2020 and May 2025. Baseline CT before T-DXd initiation was reviewed for ILAs and classified as no ILA, equivocal ILA, or definite ILA. The cumulative incidence of T-DXd-related ILD was estimated using a competing-risk approach. Results: Among 156 patients, baseline ILAs were identified in 50 patients: 21 with equivocal ILA and 29 with definite ILA. T-DXd-related ILD occurred in 31 patients (20%), including 19 of 50 patients (38%) in the ILA group and 12 of 106 patients (11%) in the non-ILA group. Baseline ILA was associated with a higher cumulative incidence of T-DXd-related ILD (subdistribution hazard ratio, 3.56; 95% CI, 1.63-7.78; P = .001). No significant difference in T-DXd-related ILD risk was detected between the equivocal and definite ILA groups. This association remained consistent in the <1.5-mm CT subgroup. No significant differences in progression-free or overall survival were observed according to baseline ILA status. Among patients with baseline ILA, 33 of 50 had ILAs first detected during prior systemic anticancer therapy. Conclusions: Baseline ILAs, including equivocal findings, were associated with an increased risk of T-DXd-related ILD. ILAs were frequently first detected during prior systemic anticancer therapy before T-DXd initiation.Keywords
This publication has 20 references indexed in Scilit:
- Clinical outcomes of interstitial lung abnormalities: a systematic review and meta-analysisScientific Reports, 2024
- Pooled analysis of drug-related interstitial lung disease and/or pneumonitis in nine trastuzumab deruxtecan monotherapy studiesESMO Open, 2022
- Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast CancerNew England Journal of Medicine, 2022
- Evolution of overall survival and receipt of new therapies by subtype among 20 446 metastatic breast cancer patients in the 2008-2017 ESME cohortESMO Open, 2021
- Association of Preexisting Interstitial Lung Abnormalities With Immune Checkpoint Inhibitor–Induced Interstitial Lung Disease Among Patients With Nonlung CancersJAMA Network Open, 2020
- Interstitial lung abnormalities detected incidentally on CT: a Position Paper from the Fleischner SocietyThe Lancet Respiratory Medicine, 2020
- CinéBreast-factors influencing the time to first metastatic recurrence in breast cancer: Analysis of real-life data from the French ESME MBC databaseThe Breast, 2020
- Pre-existing interstitial lung abnormalities are risk factors for immune checkpoint inhibitor-induced interstitial lung disease in non-small cell lung cancerRespiratory Investigation, 2019
- Interstitial lung abnormalities in treatment-naïve advanced non-small-cell lung cancer patients are associated with shorter survivalEuropean Journal of Radiology, 2015
- Identification of Early Interstitial Lung Disease in Smokers from the COPDGene StudyAcademic Radiology, 2010